Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus NORETHINDRONE AND MESTRANOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus NORETHINDRONE AND MESTRANOL.
CURRETAB vs NORETHINDRONE AND MESTRANOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Norethindrone is a progestin that suppresses gonadotropin secretion, primarily luteinizing hormone (LH), thereby inhibiting ovulation. Mestranol is a prodrug of ethinyl estradiol, an estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing follicle-stimulating hormone (FSH) and LH. The combination stabilizes the endometrium and alters cervical mucus consistency to impede sperm penetration.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
1 tablet (norethindrone 1 mg / mestranol 0.05 mg) orally once daily for 21 days, then 7 days off.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Norethindrone: 5-12 hours; Mestranol: 50-120 minutes (mestranol is rapidly demethylated to ethinyl estradiol, which has a half-life of 10-20 hours). Clinical context: Steady-state is achieved within 5-7 days; no clinically significant accumulation under normal dosing.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Renal (30-50% as metabolites), biliary/fecal (35-55% as metabolites and conjugated forms).
Category C
Category D/X
Progestin
Progestin